Home > Boards > US Listed > Computers - Hardware > Anixa Biosciences (ANIX)

US Patent & Trademark Office Issues Patent on

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paullee Member Profile
 
Followed By 16
Posts 2,351
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds PR Newswire (US) - 7/6/2020 9:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 7/2/2020 6:11:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 5:53:15 PM
Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline PR Newswire (US) - 7/2/2020 5:00:00 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/22/2020 5:07:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 10:31:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2020 10:48:45 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/9/2020 5:12:25 PM
Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays PR Newswire (US) - 6/1/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/4/2020 5:45:58 PM
Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate PR Newswire (US) - 5/4/2020 6:45:00 AM
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid B... PR Newswire (US) - 4/23/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 4:07:03 PM
Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics PR Newswire (US) - 4/20/2020 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/17/2020 3:47:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/12/2020 1:39:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/12/2020 10:27:22 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2020 2:54:45 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 3/9/2020 5:11:58 PM
Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference PR Newswire (US) - 3/2/2020 7:00:00 AM
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program PR Newswire (US) - 2/12/2020 7:00:00 AM
Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference PR Newswire (US) - 1/6/2020 7:00:00 AM
Anixa Biosciences to Present at Biotech Showcase 2020 PR Newswire (US) - 12/23/2019 7:00:00 AM
Anixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test PR Newswire (US) - 12/16/2019 6:45:00 AM
Anixa Biosciences to Host Conference Call to Discuss Plans for 2020 PR Newswire (US) - 12/13/2019 5:45:00 PM
Paullee   Wednesday, 04/17/19 09:00:50 AM
Re: None
Post # of 692 
US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
PR Newswire PR Newswire•April 17, 2019
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology.

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.

Dr. Amit Kumar, Anixa's Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist